Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.
Madrigal Pharmaceuticals…